Teva Pharmaceutical Industries



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 1.8%. By the end of trading, Teva Pharmaceutical Industries fell $1.49 (-3.5%) to $40.85 on average volume. Throughout the day, 5.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.6 million shares. The stock ranged in price between $40.64-$41.72 after having opened the day at $41.45 as compared to the previous trading day's close of $42.34. Other company's within the Drugs industry that declined today were:

NPS Pharmaceuticals Inc



), down 33.4%,

BioSpecifics Technologies Corporation



), down 10.9%,

WuXi PharmaTech (Cayman) Inc



), down 10.7%, and

Auxilium Pharmaceuticals Inc



), down 9.6%.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs; and proprietary branded pharmaceuticals in various therapeutic categories and active pharmaceutical ingredients worldwide. Teva Pharmaceutical Industries has a market cap of $34.8 billion and is part of the

health care

sector. The company has a P/E ratio of 8.6, below the average drugs industry P/E ratio of 11.2 and below the S&P 500 P/E ratio of 17.7. Shares are down 19.4% year to date as of the close of trading on Friday.

TheStreet Ratings rates Teva as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and a generally disappointing performance in the stock itself.

On the positive front,

Momenta Pharmaceuticals Inc



), up 20.9%,

Cormedix Inc



), up 16.7%,

Zalicus Inc



), up 15.8%, and

Complete Genomics Inc



), up 14%, were all gainers within the drugs industry with




) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech